公开(公告)号：US11690906B2

公开(公告)日：2023-07-04

申请号：US17096579

申请日：2020-11-12

Applicant: University of Massachusetts

Inventor： Shan Lu ,  Shixia Wang

IPC: A61K39/21 ,  A61K39/12 ,  A61K45/06 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K45/06 ,  C07K14/005 ,  C12N7/00 ,  H05K999/99 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/575 ,  A61K2039/70 ,  C12N2740/16134

Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.

公开(公告)号：US20230183375A1

公开(公告)日：2023-06-15

申请号：US17925061

申请日：2021-05-14

Applicant: Fundação Universidade Federal do ABC - UFABC ,  Technische Universität Braunschweig

Inventor： Luciano PUZER ,  Ana Flávia SANTARINE LAUREANO ,  Daniele RIBEIRO DE ARAÚJO ,  Michael HUST

IPC: C07K16/40 ,  A61K9/00 ,  A61K9/06 ,  A61K47/34

CPC classification number: C07K16/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K47/34 ,  C07K2317/622 ,  A61K2039/54

Abstract: The present invention relates to human tissue kallikrein 7 (KLK7) selective inhibitor compounds, combinations including these compounds, process to obtain the referred compounds, and methods of using the same. The present invention belongs to the field of chemistry, pharmacology and medicine.

公开(公告)号：US11672872B2

公开(公告)日：2023-06-13

申请号：US17811401

申请日：2022-07-08

Applicant: Dyne Therapeutics, Inc.

Inventor： Romesh R. Subramanian ,  Mohammed T. Qatanani ,  Timothy Weeden ,  Cody A. Desjardins ,  Brendan Quinn ,  John Najim

IPC: C07K16/28 ,  A61K39/44 ,  A61K39/00

CPC classification number: C07K16/2881 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/92

Abstract: Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of using the antibodies are also provided.

公开(公告)号：US20230144810A1

公开(公告)日：2023-05-11

申请号：US17914687

申请日：2021-03-26

Applicant: AQUAVIT PHARMACEUTICALS, INC.

Inventor： Sobin Chang ,  Daniel J. Nevrivy

IPC: A61K9/00 ,  A61K39/00 ,  A61M37/00 ,  A61B5/00

CPC classification number: A61K9/0021 ,  A61B5/411 ,  A61K39/0011 ,  A61M37/0015 ,  A61K2039/54 ,  A61M2037/003 ,  A61M2037/0046

Abstract: The present invention provides a method for generating an immune response in a subject, comprising administering to the subject’s skin an immunizing composition comprising one or more cancer antigens, wherein the composition is administered with a microneedle delivery device.

公开(公告)号：US20230141153A1

公开(公告)日：2023-05-11

申请号：US18068867

申请日：2022-12-20

Applicant: Merck Sharp & Dohme LLC

Inventor： Lan Zhang ,  Arthur Fridman ,  Eberhard Durr ,  Andrew Bett

IPC: C07K14/135 ,  A61K39/155 ,  C12N7/00

CPC classification number: C07K14/135 ,  A61K39/155 ,  C12N7/00 ,  A61K2039/54

Abstract: The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.

公开(公告)号：US20190241672A1

公开(公告)日：2019-08-08

申请号：US16388379

申请日：2019-04-18

Applicant: PHOTOCURE ASA

Inventor： Kjetil Hestdal

IPC: C07K16/30 ,  A61K41/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/30 ,  A61K41/0061 ,  A61K2039/54 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

Abstract: This invention relates to an intravesical therapy for bladder cancer.

公开(公告)号：US20190240321A1

公开(公告)日：2019-08-08

申请号：US16238933

申请日：2019-01-03

Applicant: ALBERT EINSTEIN COLLGE OF MEDICINE, INC.

Inventor： Betsy Herold

IPC: A61K39/245 ,  A61K39/12 ,  C12N7/00 ,  C07K14/005

CPC classification number: A61K39/245 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/54 ,  A61K2039/572 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2710/16643 ,  C12N2710/16662 ,  C12N2710/16671

Abstract: Methods for passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such.

公开(公告)号：US20190233539A1

公开(公告)日：2019-08-01

申请号：US16156382

申请日：2018-10-10

Applicant: MacroGenics, Inc.

Inventor： Leslie S. Johnson ,  Ling Huang ,  Nadine Tuaillon ,  Ezio Bonvini

IPC: C07K16/32 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/32 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/92

Abstract: This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

公开(公告)号：US20190216923A1

公开(公告)日：2019-07-18

申请号：US16244768

申请日：2019-01-10

Applicant: Array BioPharma Inc.

Inventor： Patrice A. Lee ,  David Chantry ,  Shannon L. Winski

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/4184 ,  A61P35/04 ,  A61K9/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K31/4184 ,  A61K2039/54 ,  A61K2039/545 ,  A61P35/00 ,  A61P35/04

Abstract: This invention relates to a method of treating cancer by administering to a patient in need thereof, over a period of time, therapeutic agents that consist essentially of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist, to a patient in need thereof.

公开(公告)号：US20190216922A1

公开(公告)日：2019-07-18

申请号：US16369209

申请日：2019-03-29

Applicant: Vrije Universiteit Brussel

Inventor： Kris Maria Magdalena Thielemans ,  Aude Bonehill

IPC: A61K39/39 ,  C12N5/0784 ,  A61K38/17 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61K38/177 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/53 ,  A61K2039/54 ,  C12N5/0639 ,  C12N2510/00 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/394 ,  Y02A50/397 ,  Y02A50/40 ,  Y02A50/401 ,  Y02A50/403 ,  Y02A50/407 ,  Y02A50/41 ,  Y02A50/466 ,  Y02A50/467 ,  Y02A50/469 ,  Y02A50/478 ,  Y02A50/48 ,  Y02A50/484

Abstract: We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TI R4 (caTIR4).